Keskin A, Tombuloglu M, Büyükkeçeci F
Department of Hematology, Faculty of Medicine, Ege University, Bornova-izmir, Turkey.
Jpn Heart J. 1994 Nov;35(6):757-63. doi: 10.1536/ihj.35.757.
The incidence of atherosclerotic and thromboembolic complications is quite high in hypertensive patients. Blood platelets and fibrinolytic activity may play an important role in the development of these complications. We investigated fibrinolytic activity and in vivo platelet release reaction in essential hypertension. Plasma levels of beta thromboglobulin (BTG), platelet factor-4 (PF4), tissue plasminogen activator (t-PA), plasminogen activator inhibitor (PAI-1) and plasminogen were determined in 36 essential hypertensive and 20 age and sex-matched control subjects. Plasma BTG levels were significantly higher in the hypertensive subjects than in controls (p < 0.05), whereas PF4 levels were similar for both groups suggesting an increase of in vivo platelet activity. PAI-1 antigen levels were found to be significantly higher in the hypertensive patients as compared to the control subjects (p < 0.01). On the other hand significant variations of t-PA antigen and plasminogen values were not observed in the two groups. These results suggest that essential hypertension is associated with decreased fibrinolytic activity and enhanced platelet activity as evidenced by high plasma levels of PAI-1 and BTG.
高血压患者发生动脉粥样硬化和血栓栓塞并发症的几率相当高。血小板和纤溶活性可能在这些并发症的发生发展中起重要作用。我们研究了原发性高血压患者的纤溶活性和体内血小板释放反应。测定了36例原发性高血压患者和20例年龄及性别匹配的对照者血浆中β-血小板球蛋白（BTG）、血小板因子4（PF4）、组织型纤溶酶原激活物（t-PA）、纤溶酶原激活物抑制剂（PAI-1）和纤溶酶原的水平。高血压患者血浆BTG水平显著高于对照组（p < 0.05），而两组的PF4水平相似，提示体内血小板活性增加。与对照者相比，高血压患者的PAI-1抗原水平显著更高（p < 0.01）。另一方面，两组中未观察到t-PA抗原和纤溶酶原值的显著变化。这些结果表明，原发性高血压与纤溶活性降低和血小板活性增强有关，PAI-1和BTG的高血浆水平证明了这一点。
